We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov. 7, 2024 -- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and...
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference PR Newswire WALTHAM, Mass., Nov. 5, 2024 WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB...
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 PR Newswire WALTHAM, Mass., Oct. 14...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -14.51 | -33.2798165138 | 43.6 | 44.38 | 23.5 | 114406 | 33.62059514 | CS |
4 | -17.69 | -37.8153056862 | 46.78 | 53.17 | 23.5 | 98424 | 43.19142995 | CS |
12 | -8.67 | -22.9608050847 | 37.76 | 53.79 | 23.5 | 110251 | 44.85421641 | CS |
26 | -0.71 | -2.38255033557 | 29.8 | 53.79 | 13.59 | 93654 | 37.88582058 | CS |
52 | 12.85 | 79.1256157635 | 16.24 | 53.79 | 13.59 | 81748 | 36.43411471 | CS |
156 | 12.85 | 79.1256157635 | 16.24 | 53.79 | 13.59 | 81748 | 36.43411471 | CS |
260 | 12.85 | 79.1256157635 | 16.24 | 53.79 | 13.59 | 81748 | 36.43411471 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions